AbbVie Inc. vs Eli Lilly and Company — Stock Comparison
AbbVie Inc. (ABBV) and Eli Lilly and Company (LLY) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Eli Lilly and Company scores ahead of AbbVie Inc. on Q·Score (7.7 vs 6.6 out of 10), led by Quality (9 vs 5.5) and Growth (9.8 vs 8.3). AbbVie Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for ABBV (+11.1%) than for LLY (+9.4%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Earnings growing 290% year-over-year on 10% revenue growth.
⚠ balance sheet warrants attention.
Earnings growing 26% year-over-year on 48% revenue growth.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ABBV vs LLY: which stock scores better overall?
Based on Q·Score, Eli Lilly and Company (LLY) scores 7.7/10 versus AbbVie Inc. (ABBV) at 6.6/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ABBV or LLY?
Eli Lilly and Company (LLY) scores higher on Growth (9.8/10 vs 8.3/10). AbbVie Inc. reports revenue growth (10.2% YoY) while Eli Lilly and Company reports (47.7% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ABBV or LLY more attractively valued?
AbbVie Inc. (ABBV) scores higher on Valuation (7.3/10 vs 6.3/10). ABBV trades at 15.1× P/E versus LLY at 25.7×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ABBV vs LLY?
There are 28 analysts covering ABBV with a consensus price target of $273.39, and 26 analysts covering LLY with a consensus target of $1297.31. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ABBV or LLY?
Eli Lilly and Company (LLY) scores higher on Quality (9/10 vs 5.5/10). Net profit margin: ABBV at 9.8%, LLY at 33.5%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ABBV or LLY?
Eli Lilly and Company (LLY) scores higher on Financial Health (5.5/10 vs 4.9/10). Market beta: ABBV at 0.28, LLY at 0.51. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ABBV and LLY?
AbbVie Inc. (ABBV) has a market capitalisation of $434.8B, while Eli Lilly and Company (LLY) has a market cap of $1.06T. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do ABBV or LLY pay dividends?
ABBV pays a dividend yield of 2.84%, while LLY pays a dividend yield of 0.58%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →